Jasper Therapeutics shares surge 10.33% intraday on positive Briquilimab data in Chronic Spontaneous Urticaria studies.
ByAinvest
Wednesday, Feb 18, 2026 11:17 am ET1min read
JSPR--
Jasper Therapeutics surged 10.33% intraday trading following the release of updated positive data from briquilimab studies in chronic spontaneous urticaria and the appointment of Jeet Mahal as CEO. The company highlighted promising results from its ETESIAN asthma trial and BEACON study investigation, alongside strategic leadership changes to drive clinical growth. Recent insider stock purchases and investor webinars further underscored confidence in the pipeline, aligning with the sharp intraday rally. These developments reinforced investor optimism about briquilimab’s therapeutic potential and operational restructuring, positioning the stock for near-term momentum.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet